Virax Biolabs Group LtdVRAXEarnings & Financial Report
Nasdaq
VRAX Q2 2026 Key Financial Metrics
Revenue
$1.6K
Gross Profit
$1.9K
Operating Profit
$-2.6M
Net Profit
$-2.3M
Gross Margin
120.0%
Operating Margin
-160788.2%
Net Margin
-145725.9%
YoY Growth
N/A
Financial Flow
Virax Biolabs Group Ltd Q2 2026 Financial Summary
Virax Biolabs Group Ltd reported revenue of $1.6K for Q2 2026, with a net profit of $-2.3M (-145725.9% margin). Cost of goods sold was $-321, operating expenses totaled $2.6M.
Key Financial Metrics
| Total Revenue | $1.6K |
|---|---|
| Net Profit | $-2.3M |
| Gross Margin | 120.0% |
| Operating Margin | -160788.2% |
| Report Period | Q2 2026 |
Income Statement
| Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|
| Revenue | $76500 | $4953 | $1608 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|
| Assets | N/A | N/A | N/A |
| Liabilities | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A |
Cash Flow
No data available for this period